The Rabies Diagnostics Market includes a broad range of diagnostic methods, technologies, sample types, and end-user categories. Market Research Future reports that the market is expected to grow from USD 2.27 billion in 2025 to USD 3.82 billion by 2035, at a CAGR of 5.34%. Increasing rabies surveillance requirements and advances in diagnostic technologies are shaping competition across these segments.

By diagnostic method, the Fluorescent Antibody Test remains a major segment. FAT accounted for approximately 44.1% of the market in 2024 because it has long been used as an established confirmatory approach in reference laboratories. Nevertheless, molecular diagnostic methods are gaining momentum because of their sensitivity and potential for broader applications.

PCR and RT-PCR platforms are projected to record an 8.89% CAGR through 2035. Their ability to support detection in challenging samples and contribute to molecular surveillance makes them increasingly attractive to modern laboratories. Rapid immunochromatographic tests are another important category, particularly for decentralized and field-based testing.

By technology, immunodiagnostics represented the largest segment in 2024, holding approximately 57.2% of revenue. Molecular diagnostics are expected to achieve faster growth, with a projected CAGR of 9.37% through 2035. The increasing adoption of molecular platforms reflects demand for sensitive detection, genotyping capabilities, and improved laboratory efficiency.

Brain tissue remains the most widely used sample category for confirmatory post-mortem testing. It accounted for approximately 50.0% of the market in 2024. At the same time, saliva-based testing is attracting interest because it can support non-invasive ante-mortem investigation. Saliva-based testing is projected to grow at a CAGR of 6.88%.

By end user, reference laboratories held approximately 47.4% of the market in 2024. These facilities remain central to confirmatory testing and national surveillance programs. Point-of-care facilities and veterinary clinics are expected to experience faster growth as portable and rapid diagnostic products become more widely available.

The competitive landscape includes companies such as Bio-Rad Laboratories, Fujirebio, Merck KGaA/MilliporeSigma, Thermo Fisher Scientific, bioMérieux, and Zoetis. These companies participate in broader diagnostic, laboratory, veterinary, and life-science markets.

Competition is increasingly focused on improving sensitivity, reducing turnaround times, simplifying sample processing, and expanding access to decentralized testing. Future competitive advantages are likely to come from integrated molecular platforms, portable devices, AI-assisted interpretation, digital connectivity, and cost-efficient solutions for emerging markets.